Insider Selling: Pulmonx Co. (NASDAQ:LUNG) Insider Sells $30,726.20 in Stock

Pulmonx Co. (NASDAQ:LUNG) insider Geoffrey Beran Rose sold 4,586 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $6.70, for a total value of $30,726.20. Following the completion of the sale, the insider now directly owns 295,433 shares of the company’s stock, valued at approximately $1,979,401.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Geoffrey Beran Rose also recently made the following trade(s):

• On Monday, June 24th, Geoffrey Beran Rose sold 1,184 shares of Pulmonx stock. The stock was sold at an average price of $6.16, for a total transaction of $7,293.44.

Pulmonx Trading Up 5.3 %

Shares of LUNG opened at $7.31 on Friday. The stock has a market capitalization of $283.74 million, a P/E ratio of -4.75 and a beta of 0.63. Pulmonx Co. has a twelve month low of $5.46 and a twelve month high of $14.84. The company has a quick ratio of 7.92, a current ratio of 8.97 and a debt-to-equity ratio of 0.37. The firm has a fifty day simple moving average of $6.92 and a two-hundred day simple moving average of $7.77.

Analyst Ratings Changes

LUNG has been the topic of several recent research reports. Wells Fargo & Company reduced their target price on shares of Pulmonx from $14.00 to $10.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. Canaccord Genuity Group raised their price objective on Pulmonx from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Finally, Lake Street Capital initiated coverage on Pulmonx in a research note on Tuesday, June 4th. They issued a “buy” rating and a $12.00 target price for the company. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $14.83.

Hedge Funds Weigh In On Pulmonx

Several hedge funds and other institutional investors have recently modified their holdings of LUNG. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Pulmonx in the second quarter worth about $37,000. Allspring Global Investments Holdings LLC lifted its holdings in Pulmonx by 609.7% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,516 shares of the company’s stock worth $79,000 after buying an additional 7,316 shares during the period. Hsbc Holdings PLC purchased a new stake in Pulmonx in the 2nd quarter worth approximately $93,000. Quest Partners LLC bought a new stake in shares of Pulmonx in the 4th quarter worth approximately $94,000. Finally, EntryPoint Capital LLC purchased a new position in shares of Pulmonx during the first quarter valued at approximately $102,000. 91.04% of the stock is owned by institutional investors.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.